Clinical Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamic Effects of a Single and Multiple Oral BAY1101042 Tablet Doses in Healthy Male Subjects
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
Age
18–45
Sex
MALE
Healthy volunteers
Accepted
You may be eligible if
The informed consent must be signed before any study specific tests or procedures are done.
Healthy male subject.
Age: 18 to 45 years (inclusive) at the screening.
Body mass index (BMI): above/equal 18 and below/equal 29.9 kg/m2.
Ability to understand and follow study-related instructions.
You may not be if
Pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal.
Subjects with thyroid disorders as evidenced by assessment of thyroid stimulating hormone (TSH) levels outside the normal reference range at screening.
Heart rate below 50 or above 90 beats/ min (at screening).
Clareo Health | Clinical Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamic Effects of a Single and Multiple Oral BAY1101042 Tablet Doses in Healthy Male Subjects
